1. Home
  2. UVV vs TRVI Comparison

UVV vs TRVI Comparison

Compare UVV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

N/A

Current Price

$53.96

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$11.48

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UVV
TRVI
Founded
1886
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
UVV
TRVI
Price
$53.96
$11.48
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$20.38
AVG Volume (30 Days)
212.3K
1.2M
Earning Date
05-11-2026
01-01-0001
Dividend Yield
6.07%
N/A
EPS Growth
N/A
N/A
EPS
3.02
N/A
Revenue
$2,922,924,000.00
N/A
Revenue This Year
$0.67
N/A
Revenue Next Year
$0.10
N/A
P/E Ratio
$17.89
N/A
Revenue Growth
7.40
N/A
52 Week Low
$49.96
$4.17
52 Week High
$67.33
$14.39

Technical Indicators

Market Signals
Indicator
UVV
TRVI
Relative Strength Index (RSI) 49.98 55.21
Support Level $53.98 $9.80
Resistance Level $56.52 $12.11
Average True Range (ATR) 1.18 0.60
MACD -0.05 0.11
Stochastic Oscillator 38.76 78.14

Price Performance

Historical Comparison
UVV
TRVI

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: